{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:28:11Z","timestamp":1790278091963,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Venetoclax, an oral BCL-2 inhibitor, has efficacy in t(11;14)-positive relapsed\/refractory multiple myeloma (RRMM), which is enhanced by dexamethasone, which promotes BCL-2 dependency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      The randomized, open-label, phase III CANOVA study (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03539744\">NCT03539744<\/jats:ext-link>\n                      ) enrolled adults with t(11;14)-positive RRMM who had received \u22652 previous lines of therapy. Patients were randomly assigned (1:1) to venetoclax-dexamethasone or pomalidomide-dexamethasone until progression or intolerable toxicity. The primary end point was independent review committee assessed\u2013progression-free survival (PFS) in the intention-to-treat population analyzed by stratified log-rank test (two-sided type I error rate, \u03b1 = .05), with hazard ratio (HR) and 95% CI estimated by stratified Cox proportional hazard model. Secondary end points included response rates, overall survival (OS), minimal residual disease (MRD) negativity rate (&lt;10\n                      <jats:sup>\u20135<\/jats:sup>\n                      ), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Overall, 263 patients were randomly assigned (venetoclax-dexamethasone, n = 133; pomalidomide-dexamethasone, n = 130). Median PFS was 9.9 months (95% CI, 6.9 to 12.6) with venetoclax-dexamethasone versus 5.8 months (95% CI, 3.8 to 9.2) with pomalidomide-dexamethasone (HR, 0.823 [95% CI, 0.596 to 1.136];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .24). Overall response and very good partial response or better rates were 62% and 39%, respectively, with venetoclax-dexamethasone versus 35% and 14% with pomalidomide-dexamethasone. MRD negativity rate was 8% with venetoclax-dexamethasone and 0% with pomalidomide-dexamethasone. Median OS was 32.4 months (95% CI, 26.4 to 40.7) with venetoclax-dexamethasone and 26.9 months (95% CI, 20.4 to 38.9) with pomalidomide-dexamethasone (HR, 0.856 [95% CI, 0.612 to 1.197]). Grade \u22653 treatment-emergent adverse event rates were 67% with venetoclax-dexamethasone versus 83% with pomalidomide-dexamethasone. There were 16 (12%) treatment-emergent deaths with venetoclax-dexamethasone versus 8 (6%) with pomalidomide-dexamethasone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The primary end point of PFS was not met. PFS and OS were numerically longer with venetoclax-dexamethasone versus pomalidomide-dexamethasone in t(11;14)-positive RRMM. Consistent with previous studies, infections were associated with venetoclax-dexamethasone; no new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-00924","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T20:59:14Z","timestamp":1765400354000},"page":"164-175","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":6,"title":["Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6553-4618","authenticated-orcid":true,"given":"Rakesh","family":"Popat","sequence":"first","affiliation":[{"name":"Haematology Department, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":true,"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":true,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Department of Medicine, Korea University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-4482","authenticated-orcid":true,"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":true,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"Division of Hematology 1, Department of Biotechnology and Health Science, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-7977","authenticated-orcid":true,"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":true,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-807X","authenticated-orcid":true,"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":true,"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, W\u00fcrzburg University Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9739-7101","authenticated-orcid":true,"given":"Silvia","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-2226","authenticated-orcid":true,"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"Department of Haematology, Singapore General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Myeloma\/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Hematological Disorders &amp; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maika","family":"Onishi","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-1769","authenticated-orcid":true,"given":"Grace","family":"Ku","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-8829","authenticated-orcid":true,"given":"Monique","family":"Dail","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabanita","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Ross","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ali","family":"Badawi","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jean","family":"Fusco","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Dobkowska","sequence":"additional","affiliation":[{"name":"Pharmacyclics Switzerland GmbH, An AbbVie Company, Schaffhausen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Arriola","sequence":"additional","affiliation":[{"name":"AbbVie, Maidenhead, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando F.","family":"Bueno","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":true,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-960X","authenticated-orcid":true,"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":true,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Haematology Department, University Hospital of Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca and Institute of Cancer Molecular and Cellular Biology and CIBERONC, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_12_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_3_12_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"e_1_3_12_4_2","first-page":"2950","article-title":"Multiple myeloma with t(11;14): Unique biology and evolving landscape","volume":"12","author":"Bal S","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R, et al: Multiple myeloma with t(11;14): Unique biology and evolving landscape. Am J Cancer Res 12:2950-2965, 2022","journal-title":"Am J Cancer Res"},{"key":"e_1_3_12_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02348-6"},{"key":"e_1_3_12_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020276"},{"key":"e_1_3_12_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007899"},{"key":"e_1_3_12_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_3_12_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788323"},{"key":"e_1_3_12_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786"},{"key":"e_1_3_12_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004146"},{"key":"e_1_3_12_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00443"},{"key":"e_1_3_12_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26083"},{"key":"e_1_3_12_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.350"},{"key":"e_1_3_12_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0730"},{"key":"e_1_3_12_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01009-1"},{"key":"e_1_3_12_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"e_1_3_12_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_12_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247"},{"key":"e_1_3_12_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_3_12_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02815"},{"key":"e_1_3_12_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_12_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00019-5"},{"key":"e_1_3_12_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0368-0"},{"key":"e_1_3_12_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114022"},{"key":"e_1_3_12_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3222"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:59:51Z","timestamp":1768431591000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,20]]}},"alternative-id":["10.1200\/JCO-25-00924"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00924","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2025-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}